证券代码：300204 证券简称：舒泰神 公告编号：2025-068 舒泰神（北京）生物制药股份有限公司 关于持股 5%以上股东减持股份触及 1%整数倍暨减持计划实施完毕的公告 公司持股 5%以上股东香塘集团有限公司保证向公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供信息一致。 舒泰神（北京）生物制药股份有限公司（以下简称"公司"或"舒泰神"） 于 2025 年 08 月 15 日披露了《关于持股 5%以上股东减持股份的预披露公告》（公 告编号 2025-045），香塘集团有限公司（以下简称"香塘集团"）计划在本减持计 划公告之日起 15 个交易日后的 3 个月内，即 2025 年 09 月 08 日至 2025 年 12 月 07 日期间（法律法规规定的窗口期不减持），通过证券交易所以大宗交易方式 减持股份不超过 477.77 万股，占公司总股本的 1%；以集中竞价方式减持股份不 超过 477.77 万股，占公司总股本的 1%。若计划减持期间公司有送股、配股、资 本公积金转增股本等股份变动事项，则对上述股份减持数量进行相应调 ...

Group 1: Financial Data - The Ministry of Finance reported that from January to August, the stamp duty revenue from securities transactions reached 118.7 billion yuan, representing a year-on-year increase of 81.7% [1] - Corporate income tax revenue for the same period was 314.77 billion yuan, with a slight year-on-year growth of 0.3% [1] - Personal income tax revenue amounted to 105.47 billion yuan, reflecting a year-on-year increase of 8.9% [1] - Vehicle purchase tax revenue was 13.34 billion yuan, showing a decline of 17.7% year-on-year [1] - Overall stamp duty revenue reached 28.44 billion yuan, with a year-on-year growth of 27.4% [1] Group 2: Industry Trends - TrendForce forecasts a 2.2% year-on-year increase in laptop shipments for the year, surpassing 180 million units, driven by favorable import conditions in Southeast Asia [2] - The retail sales of passenger cars in China from September 1 to 14 totaled 732,000 units, a year-on-year decline of 4%, but a 6% increase compared to the same period last month [2] - The retail sales of new energy vehicles during the same period reached 438,000 units, marking a year-on-year increase of 6% and a 10% increase from the previous month [2] Group 3: Corporate Developments - Shenzhen Guangdao Digital Technology Co., Ltd. was found to have fabricated sales and procurement activities, resulting in a cumulative inflation of revenue exceeding 1.4 billion yuan and costs exceeding 750 million yuan [4] - The company has been penalized with a fine of 10 million yuan and is facing potential delisting due to significant violations [5] - Peak Sports denied claims of a company-wide salary reduction, stating that the overall reduction is less than 10% and not applicable to all employees [6] - Huina Technology appointed Jiang Zexing as the new chairman, with several key personnel changes [6] - Chery Automobile's IPO in Hong Kong has reportedly received full subscription, aiming to raise up to 9.14 billion HKD [7] Group 4: Product and Project Announcements - Heng Rui Pharmaceutical's HRS-5635 injection has been included in the list of proposed breakthrough treatment varieties, showing potential for improving functional cure rates for chronic hepatitis B [8] - China Ping An completed the purchase of 74.615 million H-shares under its long-term service plan, totaling 3.875 billion yuan [9] - China Merchants Energy received the world's first methanol dual-fuel powered roll-on/roll-off ship, which can switch between traditional fuel and methanol [10] - Pingzhi Information won a bid for an artificial intelligence computing power technology service project worth approximately 170 million yuan [11] - Haixia Environmental Protection plans to invest 60.6059 million yuan in upgrading a sewage treatment project [12] - Changhua Group received a project development notification from a domestic automaker, with an estimated total sales amount of 280 million yuan over five years [13] - Xinhua Insurance reported a cumulative original insurance premium income of 158.086 billion yuan from January to August, reflecting a year-on-year increase of 21% [14]

Group 1 - The Shanghai Municipal Medical Procurement Management Office announced a suspension of procurement qualifications for certain drugs starting from September 16, 2025, due to non-compliance with price adjustment requirements by some companies [1] - A total of 10 drugs, comprising 15 specifications, are affected by this suspension, involving 11 companies including Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. and Sichuan Baili Pharmaceutical Co., Ltd. [1]

Core Viewpoint - The Shanghai Municipal Medical Procurement Management Office announced the suspension of procurement qualifications for certain drugs due to non-compliance with price adjustment requirements, affecting multiple companies including Shutaishen and Baili Pharmaceutical [1][2]. Group 1: Impact on Shutaishen - Shutaishen's product, Compound Polyethylene Glycol (3350) Quality Vitamin C Powder, is set to be launched on October 9, 2024, as the first domestic generic, aimed at bowel cleansing before medical procedures [1]. - Shutaishen has experienced a continuous decline in revenue for three years and has reported losses for five consecutive years, totaling over 1 billion yuan [2]. - In the first half of 2025, Shutaishen reported revenue of 126 million yuan, a year-on-year decline of 31.14%, with a net profit of -24.64 million yuan [2]. Group 2: Impact on Baili Pharmaceutical - Baili Pharmaceutical's product, Oral Solution of Enalapril Maleate, is also included in the suspended procurement list [2]. - Baili Pharmaceutical reported revenue of 113 million yuan in the first half of 2025, accounting for 66% of its parent company Baili Tianheng's revenue, with a net profit of -23.48 million yuan [2]. - Baili Tianheng's revenue has been declining due to falling sales in its chemical and traditional Chinese medicine product segments, which are crucial for supporting innovative drug research and development [2]. Group 3: Other Affected Products - Other drugs affected by the procurement suspension include Vancomycin Capsules, Betamethasone Ointment, Calcium Acetate Oral Solution, and several others from various pharmaceutical companies [3].

Group 1 - Shanghai Sunshine Pharmaceutical Procurement Network announced that starting from September 16, 2025, certain drug procurement qualifications will be suspended due to non-compliance with price adjustment requirements by some companies [1] - A total of 10 drugs, including 15 specifications, are affected, involving 11 companies such as Shutaishen and Sichuan Baili Pharmaceutical [1] - Shutaishen's product, Compound Polyethylene Glycol (3350) Quality Vitamin C Powder, is set to be launched on October 9, 2024, as the first domestic generic, aimed at bowel cleansing before medical procedures [1] Group 2 - Shutaishen has experienced a continuous revenue decline for three years and has reported losses for five consecutive years, accumulating over 1 billion yuan in losses [2] - In the first half of 2025, Shutaishen reported revenue of 126 million yuan, a year-on-year decline of 31.14%, with a net profit of -24.64 million yuan [2] - Sichuan Baili Pharmaceutical's oral solution of Enalapril Maleate is also included in the suspended procurement list, with Baili Pharmaceutical reporting revenue of 113 million yuan in the first half of 2025, accounting for 66% of its parent company's revenue [2] Group 3 - Other drugs affected by the procurement suspension include Vancomycin Capsules, Betamethasone Ointment, Calcium Acetate Oral Solution, and several others from various pharmaceutical companies [3]

证券时报·数据宝统计显示，舒泰神今日收盘价为38.14元，下跌1.01%，日换手率为4.54%，成交额为 7.89亿元，全天主力资金净流出7179.13万元，近5日该股累计下跌0.70%，近5日资金合计净流出3.33亿 元。 据天眼查APP显示，舒泰神(北京)生物制药股份有限公司成立于2002年08月16日。注册资本47777.2555 万人民币。（数据宝） 舒泰神9月16日大宗交易平台共发生9笔成交，合计成交量465.87万股，成交金额1.51亿元。成交价格均 为32.42元，相对今日收盘价折价15.00%。从参与大宗交易营业部来看，机构专用席位共出现在9笔成交 的买方或卖方营业部中，合计成交金额为1.51亿元，净买入1.51亿元。 进一步统计，近3个月内该股累计发生11笔大宗交易，合计成交金额为1.55亿元。 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折溢 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 价（%） | 业部 | | | 123.87 | 4015.87 | 32.42 | ...

今日(9月16日)A股共90只个股发生大宗交易，总成交24.7亿元，其中恒立液压、光启技术、舒泰神成交 额居前，成交额依次为3.08亿元、2.24亿元、1.51亿元。 机构专用席位买入额排名：舒泰神(1.51亿元)、恒立液压(1.4亿元)、杰普特(9286.55万元)、拉卡拉 (5773.6万元)、天润工业(4914万元)、利源股份(1892.4万元)、澳华内镜(1392.89万元)、益方生物-U(1121 万元)、恒通股份(1001.5万元)、奥精医疗(983.15万元)、英唐智控(978.42万元)、东方雨虹(944万元)、税 友股份(928.14万元)、天虹股份(807.38万元)、药石科技(679.04万元)、祥鑫科技(667.76万元)、福莱新材 (633.6万元)、恒工精密(502.74万元)、可靠股份(500.18万元)、海得控制(409.92万元)、海天瑞声(402.8万 元)、迦南科技(383.2万元)、盟固利(380.65万元)、康泰医学(341.66万元)、弘业期货(299.32万元)、德明 利(292.9万元)、立高食品(250.76万元)、泰尔股份(204.9万元)、云天励飞-U(2 ...

Summary of Key Points Core Viewpoint - The stock of Shuotai Shen experienced a decline of 1.01% on September 16, closing at 38.14 yuan, with significant block trades occurring totaling 4.6587 million shares and a transaction value of 151 million yuan [1][2]. Trading Activity - A total of 9 block trades were recorded, all at a price of 32.42 yuan per share, with a consistent discount of 15% from the market price [1][2]. - The first four trades involved 61,000 shares, 67,000 shares, 61,000 shares, and 91,500 shares respectively, with transaction values of approximately 19.78 million yuan, 21.72 million yuan, 19.78 million yuan, and 29.66 million yuan [1]. - The subsequent trades included 15,000 shares, 9,000 shares, 6,500 shares, 123,870 shares, and 31,000 shares, with transaction values ranging from approximately 210,000 yuan to 40.16 million yuan [2]. Recent Performance - Over the past three months, Shuotai Shen has seen a total of 11 block trades with a cumulative transaction value of 155 million yuan [3]. - In the last five trading days, the stock has decreased by 0.70%, with a net outflow of 309 million yuan in principal funds [3].

据了解，"临床默示许可"是国家药品监督管理局针对药物临床试验申请（IND）设立的一种高效审批机 制。按照规则，药物临床试验申请在提交后经过60个公示日且未收到否定或质疑意见，即视为获得默示 许可，企业可依据提交的试验方案启动相应临床试验。 值得注意的是，药捷安康于今年6月23日登陆港交所，彼时IPO发行价格为13.15港元/股。以9月16日午 间休盘价格计算，上市未满三个月，药捷安康股价涨超46倍。面对近2500亿港元的市值规模，市场不少 声音质疑药捷安康及其在研管线能否支撑起如此高的市值？ 临床进展亮眼，短期亏损与资金压力待解 21世纪经济报道记者 韩利明 9月16日，港股上市药企药捷安康（02617.HK）延续近期强劲上涨态势，截至午间休盘，报收620港元/ 股，上涨49.4%，总市值达2460.8亿港元。回溯至9月10日，药捷安康股价开启持续上行通道，其中9月 15日涨幅尤为显著，最终暴涨115.58%报415 港元/股收盘，16日药捷安康尾盘跳水转跌6%，盘中一度涨 超60%。短期股价波动引发市场广泛关注。 从消息面来看，药捷安康此次股价异动或与公司核心产品的临床进展密切相关。9月10日，药捷安康公 ...

Core Viewpoint - The National Healthcare Security Administration has announced that certain pharmaceutical companies will have their drug procurement qualifications suspended starting from September 16, 2025, due to non-compliance with drug price adjustment requirements [1]. Group 1: Drug Procurement Suspension - The suspension affects specific drugs from various manufacturers, including Staidson (Beijing) BioPharmaceuticals Co., Ltd., which produces Compound Polyethylene Glycol (3350) Electrolyte Vitamin C Powder [5][9]. - The list of drugs affected by the procurement suspension includes various formulations and dosages, indicating a broad impact across multiple products [3][4]. Group 2: Company Information - Staidson (Beijing) BioPharmaceuticals Co., Ltd. was established in August 2002 and was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on April 15, 2011, with the stock code 300204 [7][10]. - The company is currently discussing the implications of the procurement suspension internally, as confirmed by their securities department [9].